1921
Volume 99, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Disseminated strongyloidiasis is often fatal, despite treatment with oral albendazole and parenteral ivermectin (IVM). Here, we report elevated plasma IVM and albendazole sulfoxide concentrations in the context of extracorporeal membrane oxygenation and continuous renal replacement therapy in a patient with disseminated strongyloidiasis treated with subcutaneous IVM and nasogastric albenzadole. Despite elevated drug plasma concentrations, live filariform larvae were detected in endotracheal aspirates after 2 weeks of treatment.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0487
2018-09-17
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/5/tpmd180487.html?itemId=/content/journals/10.4269/ajtmh.18-0487&mimeType=html&fmt=ahah

References

  1. Kitzman D, Wei S-Y, Fleckenstein L, , 2006. Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. J Pharm Biomed Anal 40: 10131020. [Google Scholar]
  2. Chhonker YS, Edi C, Murry DJ, , 2017. LC-MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 151: 8490. [Google Scholar]
  3. Ceballos L, Krolewiecki A, Juárez M, Moreno L, Schaer F, Alvarez LI, Cimino R, Walson J, Lanusse CE, , 2018. Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers. PLoS Negl Trop Dis 12: e0005945. [Google Scholar]
  4. Marriner S, Morris D, Dickson B, Bogan J, , 1986. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30: 705708. [Google Scholar]
  5. Rose CE, Paciullo CA, Kelly DR, Dougherty MJ, Fleckenstein LL, , 2009. Fatal outcome of disseminated strongyloidiasis despite detectable plasma and cerebrospinal levels of orally administered ivermectin. J Parasitol Res 2009: 818296. [Google Scholar]
  6. Barrett J, Broderick C, Soulsby H, Wade P, Newsholme W, , 2016. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother 71: 220225. [Google Scholar]
  7. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, Bisoffi Z, , 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13: 78. [Google Scholar]
  8. Boggild AK, Libman M, Greenaway C, McCarthy A, CATMAT; , 2016. CATMAT statement on disseminated strongyloidiasis: prevention, assessment and management guidelines. Can Commun Dis Rep 42: 1219. [Google Scholar]
  9. Bogoch II, Khan K, Abrams H, Nott C, Leung E, Fleckenstein L, Keystone JS, , 2015. Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection. Am J Trop Med Hyg 93: 9496. [Google Scholar]
  10. Grein JD, Mathisen GE, Donovan S, Fleckenstein L, , 2010. Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report. Scand J Infect Dis 42: 234236. [Google Scholar]
  11. de Moura EB, Maia M de O, Ghazi M, Amorim FF, Pinhati HM, , 2012. Salvage treatment of disseminated strongyloidiasis in an immunocompromised patient: therapy success with subcutaneous ivermectin. Braz J Infect Dis 16: 479481. [Google Scholar]
  12. Turner SA, Maclean JD, Fleckenstein L, Greenaway C, , 2005. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 73: 911914. [Google Scholar]
  13. Donadello K, Cristallini S, Taccone FS, Lorent S, Vincent J-L, de Backer D, Jacobs F, , 2013. Strongyloides disseminated infection successfully treated with parenteral ivermectin: case report with drug concentration measurements and review of the literature. Int J Antimicrob Agents 42: 580583. [Google Scholar]
  14. Leung V, Al-Rawahi GN, Grant J, Fleckenstein L, Bowie W, , 2008. Failure of subcutaneous ivermectin in treating Strongyloides hyperinfection. Am J Trop Med Hyg 79: 853855. [Google Scholar]
  15. Fusco DN, Downs JA, Satlin MJ, Pahuja M, Ramos L, Barie PS, Fleckenstein L, Murray HW, , 2010. Non-oral treatment with ivermectin for disseminated strongyloidiasis. Am J Trop Med Hyg 83: 879883. [Google Scholar]
  16. Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, Fleckenstein L, Baden LR, , 2005. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 41: e5e8. [Google Scholar]
  17. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ, , 2008. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J 10: 4246. [Google Scholar]
  18. Mahanty S, Paredes A, Marzal M, Gonzalez E, Rodriguez S, Dorny P, Guerra-Giraldez C, Garcia HH, Nash T, , 2011. Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts. Antimicrob Agents Chemother 55: 211217. [Google Scholar]
  19. Thomsen EK, 2016. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 62: 334341. [Google Scholar]
  20. Skuhala T, Trkulja V, Desnica B, , 2014. Albendazolesulphoxide concentrations in plasma and hydatid cyst and prediction of parasitological and clinical outcomes in patients with liver hydatidosis caused by Echinococcus granulosus. Croat Med J 55: 146155. [Google Scholar]
  21. Paredes A, de Campos Lourenço T, Marzal M, Rivera A, Dorny P, Mahanty S, Guerra-Giraldez C, García HH, Nash TE, Cass QB, Peru the CWG; , 2013. In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium. Antimicrob Agents Chemother 57: 944949. [Google Scholar]
  22. Sarin R, Dash AP, Dua VK, , 2004. Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 799: 233238. [Google Scholar]
  23. Chhonker YS, Edi C, Murry DJ, , 2018. LC–MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 151: 8490. [Google Scholar]
  24. Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J, , 1992. Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 32: 2831. [Google Scholar]
  25. Bolfer L, Bandt C, Shih A, Buckley G, , 2013. 1132: use of single pass lipid dialysis for the treatment of avermectin toxicity. Crit Care Med 41: A286A287. [Google Scholar]
  26. Johnson CA, Simmons WD, , 2000. Dialysis of Drugs. Thousand Oaks, CA: Nephrology Pharmacy Associates, Inc.
  27. Dzierba AL, Abrams D, Brodie D, , 2017. Medicating patients during extracorporeal membrane oxygenation: the evidence is building. Crit Care 21: 66. [Google Scholar]
  28. Shekar K, 2012. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 16: R194. [Google Scholar]
  29. Venkatesan P, 1998. Albendazole. J Antimicrob Chemother 41: 145147. [Google Scholar]
  30. Dong MD, Karsenti N, Lau R, Ralevski F, Cheema K, Burton L, Klowak M, Boggild AK, , 2016. Strongyloidiasis in Ontario: performance of diagnostic tests over a 14-month period. Travel Med Infect Dis 14: 625629. [Google Scholar]
  31. Gattinoni L, Carlesso E, Langer T, , 2011. Clinical review: extracorporeal membrane oxygenation. Crit Care 15: 243. [Google Scholar]
  32. Fardet L, Généreau T, Poirot J-L, Guidet B, Kettaneh A, Cabane J, , 2007. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 54: 1827. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0487
Loading
/content/journals/10.4269/ajtmh.18-0487
Loading

Data & Media loading...

  • Received : 09 Jun 2018
  • Accepted : 19 Aug 2018
  • Published online : 17 Sep 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error